Recently, somatic mutations in the TK domain of the EGFR gene have been identified in the NSCLC of the patients who showed increased response to gefitinib, suggesting clinical utility as a predictive factor (Lynch et al, 2004; Paez et al, 2004). Here, EGFR is linked to non-small cell lung carcinoma.